Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
  1. Home
  2. Search

Refine search

Refine search

Access:
Content type:
Publication date:
Apply   From and To filters
Subject: Show more
Journals Show more
Publishers: Show more
Societies Show more
Series: Show more
Collections: Show more

Actions for selected content:

Select all | Deselect all
  • View selected items
  • Export citations
  • Download PDF (zip)
  • Save to Kindle
  • Save to Dropbox
  • Save to Google Drive

Save Search

You can save your searches here and later view and run them again in "My saved searches".

Please provide a title, maximum of 40 characters.
Cancel
×

1 results

  • Chapter 14 - Cerebral microbleeds in relation to braintrauma

  • from Section 3 - Microbleeds in relation to specific populations, diseases and neurological symptoms
  • Edited by David J. Werring, Institute of Neurology, London
  • Book:
    Cerebral Microbleeds
    Published online:
    05 July 2011
    Print publication:
    26 May 2011, pp 125-134

  • Summary

    Cerebral microbleeds (CMBs) reflect an underlying angiopathy currently thought to result mainly from hypertension or from the deposition of beta-amyloid in small and micro vessel walls. This chapter describes the prevalence of, and risk factors for, CMBs and methodological issues related to their study. CMBs can be present in up to 80% of a clinical hemorrhagic stroke sample. Most studies with a reasonable distribution of subject age and sample size show CMB prevalence increases with age. There is robust evidence that high blood pressure, measured in different ways, is a risk factor for CMB. Most genetic diseases with increased susceptibility to CMBs are rare. The only candidate susceptibility gene identified as risk modifying is APOE. Research on risk factors for CMBs will bring into better focus issues related to comorbidity with other vascular and neurodegenerative lesions and location and number of lesions.